Table 1.
Clinicopathological data and MCPyV DNA PCR, FISH, IHC, and RISH results with HPyV7 positivity of the tissues
| Clinicopathological data | MCPyV | HPyV7 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID | G | Age | MG | Thymtype | Masaoka‐Koga | Anti AChR | IS/ster. | M1/M2 (178 bp) | VP1 (351 bp) | LT3 (308 bp) | MCPyV FISH | MCPyV RISH | MCPyV IHC CM2B4 | sTAg‐PCR | LTAg‐PCR | FISH | IHC 2t10 |
| 1–1 | F | 73 | + | B1/B2 | I | + | + | − | − | NA | + | + | + | − | |||
| 1–2 | F | 75 | + | B1/B2 | I | + | + | − | − | NA | + | + | + | − | |||
| 1–11 | F | 34 | + | B2 | I | + | − | − | − | − | − | − | ++ | − | |||
| 1–12 | F | 36 | + | A | I | − | + | + | (+) | − | + | n.d. | − | − | − | − | − |
| 1–16 | F | 34 | + | A | I | + | + | + | (+) | − | + | n.d. | − | − | − | − | − |
| 1–17 | M | 69 | + | AB | I | + | + | − | − | − | − | + | ++ | − | |||
| 1–18 | F | 47 | + | AB | I | + | + | − | − | − | + | + | − | − | |||
| 1–19 | M | 68 | − | AB | I | NA | NA | − | − | − | + | + | ++ | + | |||
| 1–21 | F | 38 | + | AB | I | + | − | − | − | − | − | + | − | − | |||
| 1–22 | M | 65 | + | AB/B2 | I | + | − | + | − | (+) | NA | n.d. | − | − | − | − | − |
| 1–28 | M | 38 | − | B1 | I | NA | NA | − | − | − | − | − | − | − | |||
| 1–31 | F | 82 | + | A | I | + | + | + | − | − | + | + | + | + | |||
| 1–32 | M | 47 | + | B2 | I | + | − | + | − | − | n.d. | − | n.d. | − | − | − | − |
| 1–34 | M | 59 | − | AB | I | NA | NA | − | − | − | + | − | ++ | + | |||
| 1–36 | F | 82 | − | AB | I | NA | NA | − | − | − | − | (+) | ++ | + | |||
| 1–39 | F | 78 | − | B1 | I | NA | NA | − | − | − | − | − | − | − | |||
| 1–43 | F | 78 | − | AB | I | NA | NA | + | + | − | + | n.d. | + | − | − | ++ | (+) |
| 1–23 | M | 37 | + | AB | IIA | + | − | + | − | − | + | − | + | + | |||
| 1–24 | M | 68 | + | B2 | IIA | + | − | − | − | − | + | + | ++ | + | |||
| 1–33 | F | 43 | + | B2 | IIA | + | − | − | − | − | − | − | ++ | + | |||
| 1–35 | M | 45 | + | AB | IIA | + | − | − | − | − | + | + | ++ | + | |||
| 1–37 | M | 77 | + | AB | IIA | + | − | − | − | − | − | − | +++ | (+) | |||
| 1–38 | F | 80 | + | AB | IIA | + | + | − | − | + | − | − | − | − | |||
| 1–3 | F | 57 | + | B2/B3 | IIB | + | − | + | − | − | + | + | + | + | |||
| 1–5 | M | 37 | + | B3 | IIB | + | + | + | − | − | + | + | ++ | + | |||
| 1–7 | F | 79 | + | A | IIB | − | − | + | − | − | + | + | ++ | (+) | |||
| 1–8 | M | 58 | + | A/B2 | IIB | + | − | (+) | (+) | + | ++ | (+) | (+) | + | + | +++ | (+) |
| 1–9 | M | 64 | − | B2 | IIB | NA | NA | − | − | − | + | + | ++ | (+) | |||
| 1–15 | F | 53 | + | B3 | IIB | + | + | − | − | − | − | − | + | − | |||
| 1–26 | M | 65 | − | AB | IIB | NA | NA | − | − | (+) | − | − | − | − | − | − | − |
| 1–42 | F | 57 | + | AB | IIB | + | − | − | − | − | − | − | − | − | |||
| 1–10 | F | 73 | + | B3 | III | + | + | − | − | − | − | − | − | − | |||
| 1–13 | F | 54 | − | B2 | III | NA | NA | − | − | − | − | + | + | (+) | |||
| 1–20 | M | 64 | − | B3 | III | NA | NA | ++ | ++ | ++ | + | n.d. | − | − | − | − | − |
| 1–41 | M | 65 | − | B3 | III | NA | NA | − | − | − | + | (+) | +++ | + | |||
| 1–25 | M | 37 | + | B2 | IVA | + | + | + | + | NA | + | n.d. | + | n.d. | n.d. | n.d. | n.d. |
| 25/36 | 24/25 | 12/25 | 13/36 | 8/36 | 4/33 | 6/7 | 1/3 | 3/7 | 15/35 | 17/35 | 22/35 | 15/35 | |||||
| 69.4% | 96.0% | 48.0% | 36.1% | 22.2% | 12.1% | 85.7% | 33.3% | 37.5% | 42.9% | 48.6% | 62.9% | 42.9% | |||||
Clinicopathological data and the results of Merkel cell polyomavirus (MCPyV) DNA PCR, fluorescence in situ hybridization (FISH), immunohistochemistry (IHC) and RNA in situ hybridization (RISH) in relation to the recently reported HPyV7 positivity in these thymomas as published by Rennspiess et al., 2017. MCPyV‐negative ID‐32 and ID‐26 were used as negative controls for IHC and RISH.
Anti‐AChR, anti acetylcholine receptor antibodies; bp, base pairs; F, female; G, gender; HPyV7, human polyomavirus 7; ID, laboratory identification; IS/Ster., immunosuppression/steroids; LTAg, large T‐antigen; M, male; MG, myasthenia gravis; sTAg, small T‐antigen; Thym. type, thymoma type; ++, strong positive; +, positive; (+), weak positive; −, negative; NA, not applicable; n.d., not done.